I’ll let you in on a little secret: I’m not supposed to attend the health care conference in Boston organized by the investment bank Cowen each March. Technically, it’s a media-free event.

But as long as I behave myself and don’t live-tweet from the sessions, Cowen tolerates my presence. I’m grateful because the conference’s unique setup — investors and doctor-specialists critique approved and experimental drugs across nearly two dozen disease areas — offers a helpful sentiment check on biotech and pharma companies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy